SZN-8141 / Surrozen - LARVOL DELTA

Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema (GlobeNewswire) - "SZN-8141 will be evaluated in a Phase 1b/2a clinical trial in DME called DUET, designed to assess safety, tolerability, and early signs of biological and clinical activity. Surrozen expects to initiate the DUET Phase 1b/2a study in DME patients by year-end 2026, with initial data anticipated in the second half of 2027."

IND • New P1/2 trial • P1/2 data • Diabetic Macular Edema

DUET: A First-in-human Trial of SZN-8141 in Diabetic Macular Edema (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Surrozen Operating, Inc.

First-in-human • New P1 trial • Diabetic Macular Edema • Ophthalmology

Wnt signaling activation synergizes with VEGF inhibition in preclinical models of retinal vascular diseases (ARVO 2026) - "The synergistic effect of SZN-8141 in preclinical models demonstrates superior efficacy to current standard of care, suggesting that combining Wnt activation—promoting vascular stability and repair, with VEGF inhibition—reducing pathological vessel growth and leakage, may offer improved efficacy, longer-lasting results, and reduced injection frequency compared to current therapies. Our findings also provide evidence that therapeutic strategies targeting the Wnt signaling pathway, in conjunction with other pathways implicated in vascular permeability—such as IL-6 signaling—may hold promise for future interventions."

Preclinical • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • IL6

The Company continues to progress its lead candidates, SZN-8141 and SZN-8143, in retinal diseases and remains on track to submit an Investigational New Drug (IND) application for SZN-8141 in the second half of 2026 (GlobeNewswire) - "The Company presented evidence of preclinical efficacy of our novel bi-functional antibody SZN-8141 at its Poster Presentation during the Association for Research in Vision and Ophthalmology (2026 ARVO) in May 2026. By synergizing actions of Wnt activation and VEGF inhibition, SZN-8141 demonstrates superiority over monotherapies in preclinical models, suggesting the potential for improved outcomes compared to current therapies such as anti-VEGF standard of care."

IND • Preclinical • Age-related Macular Degeneration • Diabetic Macular Edema

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases (GlobeNewswire) - "Surrozen, Inc...today announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. The Company also announced a private placement consisting of two tranches in aggregate up to $175 million in gross proceeds to fund multiple ophthalmology programs through initial Phase 1 safety, tolerability and efficacy studies...The two lead candidates for the treatment of retinopathies include SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6)...The Company will discontinue development of SZN-043 in severe alcohol associated hepatitis....The second closing is subject to the receipt of clearance from the FDA of the Company’s Investigational New Drug Application for SZN-8141, expected in 2026."

Discontinued • Financing • IND • Diabetic Macular Edema • Hepatology • Ophthalmology • Wet Age-related Macular Degeneration